Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
1.
Muscle Nerve ; 69(4): 422-427, 2024 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-38334356

RESUMO

INTRODUCTION/AIMS: The clinical presentation of multifocal motor neuropathy (MMN) may mimic early amyotrophic lateral sclerosis (ALS) with predominant lower motor neuron (LMN) involvement, posing a diagnostic challenge. Both diseases have specific treatments and prognoses, highlighting the importance of early diagnosis. The aim of this study was to assess the diagnostic value of serum neurofilament light chain (NfL) in differentiating MMN from LMN dominant ALS. METHODS: NfL was measured in serum in n = 37 patients with MMN and n = 37 age- and sex-matched patients with LMN dominant ALS, to determine the diagnostic accuracy. Clinical and demographic data were obtained at the time of NfL sampling. RESULTS: Serum NfL concentration was significantly lower in MMN patients compared to ALS patients (mean 20.7 pg/mL vs. 59.4 pg/mL, p < .01). NfL demonstrated good diagnostic value in discriminating the two groups (AUC 0.985 [95% CI 0.963-1.000], sensitivity 94.6%, specificity 100%, cut-off 44.00 pg/mL). DISCUSSION: NfL could be a helpful tool in differentiating MMN from LMN dominant ALS in those patients in whom electrophysiological and clinical examinations remain inconclusive early in the diagnostic process.


Assuntos
Esclerose Lateral Amiotrófica , Polineuropatias , Humanos , Esclerose Lateral Amiotrófica/diagnóstico , Biomarcadores , Filamentos Intermediários , Prognóstico , Polineuropatias/diagnóstico , Proteínas de Neurofilamentos
3.
J Neurol ; 265(12): 2834-2840, 2018 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-30259176

RESUMO

BACKGROUND AND OBJECTIVES: Multifocal motor neuropathy (MMN) is a rare neuropathy and detailed descriptions of larger patient cohorts are scarce. The objective of this study was to evaluate epidemiological, clinical, and laboratory features of MMN patients and their response to treatment in Austria and to compare these data with those from the literature. METHODS: Anonymized demographic and clinical data about MMN patients until 31.12.2017 were collected from registered Austrian neurologists. Exploratory statistics on clinical and laboratory features as well as treatment regimens and responses were performed. RESULTS: 57 Patients with MMN were identified, resulting in a prevalence of 0.65/100.000. Mean age of onset was 44.1 ± 13.1 years, the diagnostic delay 5.5 ± 8.4 years. In 77% of patients, symptom onset was in the upper limbs, and in 92%, it occurred in distal muscles. Proximal onset was never observed in the lower limbs. At the final follow-up, the majority of patients had atrophy (88%) in affected regions. Definite motor conduction blocks (CB) were found in 54 patients. Anti-GM1-IgM antibodies were present in 43%. Treatment with intravenous immunoglobulins improved muscle strength and INCAT score initially, but at last follow-up, both scores deteriorated to values before treatment. DISCUSSION: The findings of the present study corroborate the previous findings in MMN. Onset typically occurs in the upper limbs and mostly distal, CBs are found in the majority of cases, while anti-GM1-IgM antibodies are detected in only approximately 40%. Our study underlines that the initial good response to treatment fades over time.


Assuntos
Doença dos Neurônios Motores/epidemiologia , Doença dos Neurônios Motores/terapia , Adolescente , Adulto , Idade de Início , Idoso , Áustria/epidemiologia , Autoanticorpos/metabolismo , Feminino , Seguimentos , Gangliosídeo G(M1)/imunologia , Humanos , Imunoglobulina M/metabolismo , Masculino , Pessoa de Meia-Idade , Doença dos Neurônios Motores/fisiopatologia , Neurologistas , Prevalência , Inquéritos e Questionários , Adulto Jovem
SELEÇÃO DE REFERÊNCIAS
Detalhe da pesquisa